… Dapagliflozin in patients with heart failure and reduced ejection fraction.  … Individuals with
type 2 diabetes were to continue to receive their glucose-lowering treatments, but these could …

… This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the … for
the end point of recurrent heart failure hospitalizations and cardiovascular death by means of a …

… patients with CKD and HF, with and without type 2 diabetes, reporting the effects of dapagliflozin
… at least 50%, end-stage kidney disease or death from cardiovascular disease or kidney …

… in a lower rate of cardiovascular death or hospitalization for … dapagliflozin demonstrated
that dapagliflozin reduced risk of worsening HF or death from cardiovascular causes for patients …

… effects on morbidity and mortality in patients with Type 2 diabetes and concurrent heart failure,
acute MI and renal failure are likely to see the usage of dapagliflozin in patients with these …

… of dapagliflozin in patients with type 2 diabetes mellitus (… data and evaluate the protective
effects of dapagliflozin against HF. We … estimate the effects of dapagliflozin in patients with HF …

… We assessed the effect of dapagliflozin on new-onset type 2 diabetes in a pooled analysis
of … The primary composite outcome was worsening heart failure or death from cardiovascular …

… the effect of dapagliflozin on the incidence of ventricular arrhythmias and sudden death in
patients with heart failure … activities in patients with myocardial infarction and type 2 diabetes, a …

… of hospitalization for heart failure or cardiovascular death, and all-cause death. In a … disease,
regardless of concomitant type 2 diabetes. Here, we report the effects of dapagliflozin on the …

… cardiovascular outcomes in patients with type 2 diabetes (19). In our observation, dapagliflozin
could reduce heart failure … mortality in patients with type 2 diabetes mellitus and heart …